Table of Contents
DelveInsight’s, “LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists-Pipeline Insights, 2016”, report provides comprehensive insight and understanding for all the pipeline drugs that fall under LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists. With the emerging immune-oncology therapeutic strategy for T-cell-mediated diseases, companies are focusing on the development of immune-check inhibitors like Lag-3, OX-40 and TIM-3 inhibitors which gained importance in recent years.
Report highlights that majorly development is seen for Lag-3 antagonist, with the lead drug of Prima BioMed in Phase II stage of development. In case of OX-40 agonists close to 4 drugs are in Phase I stage of development with AstraZeneca having its 2 drug candidates in Phase I. Majorly drug candidates are seen in early stages of development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists.
The Report gives insights on 33+ products with 20+ different technologies. The Report also provides LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists related therapeutic assessments by molecule type, route of administration, monotherapy and combination products.
-DelveInsight’s report provides a LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Landscape across the globe
-The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
-Coverage of the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
-The report reviews key players involved in the therapeutics development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists and also provide company profiling
-Pipeline products coverage based on various stages of development from NDA filings to discovery.
-Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Reason to Buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists
- Identify different type of technologies involved in the development of the therapeutics.
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Track your competitors and develop strategic initiatives to support your drug development activities.
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists pipeline in-depth
- Understand the market and choose right partners for in-licensing and out licensing for your valuable assets
Please note: this report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
The global clinical trial imaging market is projected to reach USD 1069.7 million by 2021 from USD 773.4 million in 2016, at a CAGR of 6.7% from 2016 to 2021. Increase in R&D spending and growth in the ...
The global proteomics market is projected to reach USD 21.87 billion by 2021, at a CAGR of 11.7% during the forecast period of 2016 to 2021. Growth in this market is majorly driven by the rising acceptance ...
This report by Persistence Market Research on the global high content screening market for the period 2016–2025 presents an outlook of the market across the globe. The primary objective of the report ...